<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>Wiley-Blackwell</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24843652</article-id><article-id pub-id-type="pmc">4019275</article-id><article-id pub-id-type="doi">10.1111/jdi.12004</article-id><article-id pub-id-type="publisher-id">JDI12004</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Science and Care</subject></subj-group></subj-group></article-categories><title-group><article-title>Combination therapy with an angiotensin&#x02010;converting&#x02010;enzyme inhibitor and an angiotensin <styled-content style="fixed-case">II</styled-content> receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy</article-title><alt-title alt-title-type="left-running-head">Nakamura <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12004-cr-0001" contrib-type="author"><name><surname>Nakamura</surname><given-names>Akihiko</given-names></name><xref ref-type="aff" rid="jdi12004-aff-0001"><sup>1</sup></xref><xref ref-type="aff" rid="jdi12004-aff-0002"><sup>2</sup></xref></contrib><contrib id="jdi12004-cr-0002" contrib-type="author"><name><surname>Shikata</surname><given-names>Kenichi</given-names></name><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="jdi12004-aff-0003"><sup>3</sup></xref><xref ref-type="aff" rid="jdi12004-aff-0004"><sup>4</sup></xref></contrib><contrib id="jdi12004-cr-0003" contrib-type="author"><name><surname>Nakatou</surname><given-names>Tatsuaki</given-names></name><xref ref-type="aff" rid="jdi12004-aff-0002"><sup>2</sup></xref></contrib><contrib id="jdi12004-cr-0004" contrib-type="author"><name><surname>Kitamura</surname><given-names>Takuya</given-names></name><xref ref-type="aff" rid="jdi12004-aff-0002"><sup>2</sup></xref></contrib><contrib id="jdi12004-cr-0005" contrib-type="author"><name><surname>Kajitani</surname><given-names>Nobuo</given-names></name><xref ref-type="aff" rid="jdi12004-aff-0002"><sup>2</sup></xref><xref ref-type="aff" rid="jdi12004-aff-0003"><sup>3</sup></xref></contrib><contrib id="jdi12004-cr-0006" contrib-type="author"><name><surname>Ogawa</surname><given-names>Daisuke</given-names></name><xref ref-type="correspondence-address" rid="correspondenceTo">*</xref><xref ref-type="aff" rid="jdi12004-aff-0003"><sup>3</sup></xref><xref ref-type="aff" rid="jdi12004-aff-0005"><sup>5</sup></xref></contrib><contrib id="jdi12004-cr-0007" contrib-type="author"><name><surname>Makino</surname><given-names>Hirofumi</given-names></name><xref ref-type="aff" rid="jdi12004-aff-0003"><sup>3</sup></xref></contrib></contrib-group><aff id="jdi12004-aff-0001"><label><sup>1</sup></label><institution>Osafune Clinic</institution><named-content content-type="city">Okayama</named-content><country>Japan</country></aff><aff id="jdi12004-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Internal Medicine</named-content><institution>Okayama Saiseikai General Hospital</institution><named-content content-type="city">Okayama</named-content><country country="JP">Japan</country></aff><aff id="jdi12004-aff-0003"><label><sup>3</sup></label><institution>Department of Medicine and Clinical Science</institution><named-content content-type="city">Okayama</named-content><country country="JP">Japan</country></aff><aff id="jdi12004-aff-0004"><label><sup>4</sup></label><institution>Center for Innovative Clinical Medicine</institution><institution>Okayama University Hospital</institution><named-content content-type="city">Okayama</named-content><country country="JP">Japan</country></aff><aff id="jdi12004-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Diabetic Nephropathy</named-content><institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</institution><named-content content-type="city">Okayama</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Corresponding authors. Kenichi Shikata Tel.: +81&#x02010;86&#x02010;235&#x02010;7235<break/>
Fax: +81&#x02010;86&#x02010;222&#x02010;5214; E&#x02010;mail address: <email>shikata@md.okayama-u.ac.jp</email><break/>
Daisuke Ogawa Tel.: +81&#x02010;86&#x02010;235&#x02010;7235; Fax: +81&#x02010;86&#x02010;222&#x02010;5214<break/>
E&#x02010;mail address: <email>daiogawa@md.okayama-u.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="ppub"><day>18</day><month>3</month><year>2013</year></pub-date><volume>4</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/jdi.2013.4.issue-2</issue-id><fpage>195</fpage><lpage>201</lpage><history><date date-type="received"><day>03</day><month>4</month><year>2012</year></date><date date-type="rev-recd"><day>03</day><month>8</month><year>2012</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2012</year></date></history><permissions><copyright-statement content-type="issue-copyright">&#x000a9; 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd</copyright-statement><copyright-statement content-type="article-copyright">&#x000a9; 2012 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd</copyright-statement></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:jdi-4-195.pdf"/><abstract abstract-type="main" id="jdi12004-abs-0001"><title>Abstract</title><sec id="jdi12004-sec-0001"><title>Aims/Introduction</title><p>Recent studies have pointed to the effectiveness of combination therapy with an angiotensin&#x02010;converting&#x02010;enzyme inhibitor (<styled-content style="fixed-case">ACEI</styled-content>) and an angiotensin receptor blocker (<styled-content style="fixed-case">ARB</styled-content>) for diabetic nephropathy. However, some controversy over this combination treatment remains and the mechanisms underlying its renoprotective effects have not been fully clarified. Therefore, we compared the renoprotective effects of imidapril (<styled-content style="fixed-case">ACEI</styled-content>) and losartan (<styled-content style="fixed-case">ARB</styled-content>) combination therapy with losartan monotherapy in patients with diabetic nephropathy. We also compared the anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects of these two treatments.</p></sec><sec id="jdi12004-sec-0002"><title>Materials and Methods</title><p>A total of 32 <styled-content style="fixed-case">J</styled-content>apanese patients with type&#x000a0;2 diabetes and nephropathy were enrolled. Patients were randomized to either 100&#x000a0;mg/day losartan (<italic>n</italic>&#x000a0;=&#x000a0;16) or 50&#x000a0;mg/day losartan plus 5&#x000a0;mg/day imidapril (<italic>n</italic>&#x000a0;=&#x000a0;16). We evaluated clinical parameters, serum concentrations of high&#x02010;sensitivity <styled-content style="fixed-case">C</styled-content>&#x02010;reactive protein (hs&#x02010;<styled-content style="fixed-case">CRP</styled-content>), soluble intercellular adhesion molecule&#x02010;1 (s<styled-content style="fixed-case">ICAM</styled-content>&#x02010;1), interleukin&#x02010;18 (<styled-content style="fixed-case">IL</styled-content>&#x02010;18) and monocyte chemotactic protein&#x02010;1 (<styled-content style="fixed-case">MCP</styled-content>&#x02010;1), and the urinary concentrations of <styled-content style="fixed-case">IL</styled-content>&#x02010;18, <styled-content style="fixed-case">MCP</styled-content>&#x02010;1 and 8&#x02010;hydroxy&#x02010;2&#x02032;&#x02010;deoxyguanosine (8&#x02010;<styled-content style="fixed-case">OH</styled-content>d<styled-content style="fixed-case">G</styled-content>) at 24 and 48&#x000a0;weeks after starting treatment.</p></sec><sec id="jdi12004-sec-0003"><title>Results</title><p>Blood pressure was not significantly different between the two groups. The serum levels of hs&#x02010;<styled-content style="fixed-case">CRP</styled-content>, s<styled-content style="fixed-case">ICAM</styled-content>&#x02010;1 and IL&#x02010;18, as well as urinary excretion of albumin, <styled-content style="fixed-case">IL</styled-content>&#x02010;18 and 8&#x02010;<styled-content style="fixed-case">OH</styled-content>d<styled-content style="fixed-case">G</styled-content> decreased significantly in the combination therapy group at 48&#x000a0;weeks. The percent decreases in serum <styled-content style="fixed-case">IL</styled-content>&#x02010;18 concentrations and urinary <styled-content style="fixed-case">IL</styled-content>&#x02010;18 and 8&#x02010;<styled-content style="fixed-case">OH</styled-content>d<styled-content style="fixed-case">G</styled-content> were significantly greater in the combination therapy group than in the monotherapy group.</p></sec><sec id="jdi12004-sec-0004"><title>Conclusions</title><p>Combination therapy with an <styled-content style="fixed-case">ACEI</styled-content> and an <styled-content style="fixed-case">ARB</styled-content> could be beneficial for treating diabetic nephropathy through its anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jdi12004-kwd-0001">Combination</kwd><kwd id="jdi12004-kwd-0002">Diabetic nephropathy</kwd><kwd id="jdi12004-kwd-0003">Renin&#x02013;angiotensin system</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Education, Culture, Sports, Science and Technology</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Ministry of Health, Labour and Welfare of Japan</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Takeda Science Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Naito Foundation</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Japan Foundation for Applied Enzymology</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Ryobi Teien Memory Foundation</funding-source></award-group></funding-group><counts><page-count count="7"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12004</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2013</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLM version:3.9.3 mode:remove_FC converted:04.02.2014</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation"><mixed-citation publication-type="self-citation" id="jdi12004-cit-1001">(<source>J Diabetes Invest</source>, doi: 10.1111/jdi.12004, <year>2013</year>)</mixed-citation></p></notes></front><body><sec sec-type="intro" id="jdi12004-sec-0005"><title>Introduction</title><p>It is widely accepted that chronic inflammation is profoundly involved in the development of atherosclerosis<xref rid="jdi12004-bib-0001" ref-type="ref">1</xref>. Adhesion molecules, pro&#x02010;inflammatory cytokines and chemokines, including soluble intercellular adhesion molecule&#x02010;1 (sICAM&#x02010;1), interleukin&#x02010;18 (IL&#x02010;18) and monocyte chemotactic protein&#x02010;1 (MCP&#x02010;1), are involved in the pathogenesis of diabetic nephropathy as well as atherosclerosis<xref rid="jdi12004-bib-0002 jdi12004-bib-0003" ref-type="ref">2</xref>. C&#x02010;reactive protein (CRP) is a good marker for cardiovascular risk<xref rid="jdi12004-bib-0004" ref-type="ref">4</xref>, and is a precipitating factor for diabetic nephropathy<xref rid="jdi12004-bib-0005" ref-type="ref">5</xref>. Angiotensin&#x000a0;II, which is produced by the renin&#x02013;angiotensin system (RAS), is known to promote inflammation<xref rid="jdi12004-bib-0006" ref-type="ref">6</xref>. Inhibition of the RAS and associated inflammation might be renoprotective in chronic renal diseases, including diabetic nephropathy<xref rid="jdi12004-bib-0006 jdi12004-bib-0007" ref-type="ref">6</xref>.</p><p>Oxidative stress is a critical pathogenic component of atherosclerosis and diabetic nephropathy<xref rid="jdi12004-bib-0008" ref-type="ref">8</xref>. After the onset of renal disorders, the levels of pro&#x02010;inflammatory cytokines and oxidative stress begin to increase, inducing cardiovascular diseases through vascular endothelial dysfunction<xref rid="jdi12004-bib-0009" ref-type="ref">9</xref>. Furthermore, an increase in oxidative stress has been reported in hyperglycemic rats<xref rid="jdi12004-bib-0010" ref-type="ref">10</xref>. While activation of the RAS increases oxidative stress, angiotensin&#x02010;converting enzyme inhibitors (ACEI)<xref rid="jdi12004-bib-0011" ref-type="ref">11</xref> and angiotensin&#x000a0;II type&#x000a0;1 receptor blockers (ARB)<xref rid="jdi12004-bib-0012" ref-type="ref">12</xref> inhibit oxidative stress.</p><p>Combination therapy with an ACEI and an ARB has been considered in several renal diseases to protect the kidney by potently inhibiting RAS activity<xref rid="jdi12004-bib-0013" ref-type="ref">13</xref>. In the context of diabetic nephropathy<xref rid="jdi12004-bib-0006 jdi12004-bib-0013 jdi12004-bib-0014" ref-type="ref">6</xref>, combination therapy was found to reduce albuminuria. However, most of the studies testing ACEI/ARB combination therapy in diabetic nephropathy were short&#x02010;term observational studies, and clinical studies attempting to elucidate the mechanisms underlying these renoprotective effects are not sufficient<xref rid="jdi12004-bib-0015" ref-type="ref">15</xref>.</p><p>In patients with diabetic nephropathy, ACEI/ARB combination therapy is expected to have more potent anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects than monotherapy at the systemic and local levels in the kidney. Combination therapy might also inhibit the development or progression of atherosclerosis and diabetic nephropathy more potently than monotherapy. However, to our knowledge, no clinical studies have evaluated the anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects of combination therapy. Therefore, we carried out a randomized controlled study of ACEI/ARB combination therapy vs ARB monotherapy in patients with type&#x000a0;2 diabetes and early nephropathy to compare the anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects of these therapies.</p></sec><sec sec-type="materials|methods" id="jdi12004-sec-0006"><title>Materials and Methods</title><sec id="jdi12004-sec-0007"><title>Study Design</title><p>Patients meeting the following inclusion criteria were eligible for the present study: age 30&#x02013;74&#x000a0;years, diagnosed with type&#x000a0;2 diabetes, disease duration &#x02265;7&#x000a0;years, diagnosis of diabetic neuropathy and retinopathy, creatinine clearance (C<sub>Cr</sub>; determined using the Cockcroft&#x02013;Gault formula) &#x0003e;60&#x000a0;mL/min and urinary albumin/creatinine ratio (ACR) &#x0003e;30&#x000a0;mg/gCr. The diagnosis of type&#x000a0;2 diabetes was made according to the World Health Organization criteria.</p><p>Patients meeting any of the following criteria were excluded from the present the study: patients with chronic inflammatory disease or malignancies, pregnant women or women who wished to become pregnant, patients with renovascular hypertension, patients with hemoglobin A1C (A1C; National Glycohemoglobin Standardization Program) &#x0003e;9.4%; patients with blood pressure (BP) &#x0003e;180/110&#x000a0;mmHg and patients who had participated in another clinical trial within 3&#x000a0;months before enrolling in the present study. At the discretion of the investigator, patients who had previously used an ACEI or ARB that could not be washed out were also excluded. Concomitant use of steroids, potassium&#x02010;sparing diuretics, digoxin, or anti&#x02010;arrhythmic drugs except for &#x003b2;&#x02010;blockers and calcium channel blockers was not allowed. Concomitant use of new statins or thiazolidinedione derivatives was not allowed during the washout or observation periods. Blood glucose levels were to be controlled by adjusting the dose of medications already in use.</p><p>Written informed consent was obtained from all participants. The present study was approved by the Ethics Committee of Okayama Saiseikai General Hospital.</p><p>The design of the present study is summarized in Figure&#x000a0;<xref rid="jdi12004-fig-0001" ref-type="fig">1</xref>a. During the washout period, previous ACEIs or ARBs were discontinued and switched to amlodipine (5&#x000a0;mg/day). The observation period was started 8&#x000a0;weeks after starting treatment with amlodipine. In the present study, we treated patients with losartan (ARB) and imidapril (ACEI) or losartan alone during the observation period. Amlodipine was stopped when starting combination or monotherapy.</p><fig fig-type="Figure" xml:lang="en" id="jdi12004-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(a) Study design. During the washout period, angiotensin converting enzyme inhibitors (<styled-content style="fixed-case">ACEI</styled-content>) and angiotensin receptor blockers (<styled-content style="fixed-case">ARB</styled-content>) were discontinued and switched to amlodipine (5&#x000a0;mg/day). At the end of the washout period, patients were allocated to either monotherapy (100&#x000a0;mg/day losartan) or combination therapy (50&#x000a0;mg/day losartan plus 5&#x000a0;mg/day imidapril) and followed for 48&#x000a0;weeks. (b) Patient disposition. Four patients were excluded from this study during the washout period, including one patient who refused to participate in the study, two patients with an <styled-content style="fixed-case">ACR</styled-content>&#x000a0;&#x0003c;&#x000a0;30&#x000a0;mg/g<styled-content style="fixed-case">C</styled-content>r and one patient with <styled-content style="fixed-case">C</styled-content><sub>Cr</sub>&#x000a0;&#x0003c;&#x000a0;60&#x000a0;mL/min. Of the 32 patients who started the observation period, 28 were treated for 48&#x000a0;weeks and were included in the analysis.</p></caption><graphic xlink:href="jdi-4-195-g1"><alt-text>image</alt-text></graphic></fig><p>For losartan monotherapy, the losartan dose was 100&#x000a0;mg/day. In combination therapy, the doses of losartan and imidapril were 50 and 5&#x000a0;mg/day, respectively. The first patient enrolled in the study was allocated to monotherapy, with subsequent patients allocated to one of the two therapies.</p><p>During the observation period, patients were to be discontinued or withdrawn from the study if BP could not be maintained at &#x0003c;180/110&#x000a0;mmHg, C<sub>Cr</sub> decreased to 60&#x000a0;mL/min, serum creatinine increased from baseline by &#x02265;30%, or if an adverse drug reaction possibly related to therapy occurred.</p></sec><sec id="jdi12004-sec-0008"><title>Data Collection</title><p>After the baseline visit, patients were instructed to visit the hospital at 8, 16, 24 and 48&#x000a0;weeks. At each visit, physical findings, BP, hematological parameters, urinalysis parameters and complications were assessed (Figure&#x000a0;<xref rid="jdi12004-fig-0001" ref-type="fig">1</xref>b). Venous blood and urine samples were obtained in the early morning after an overnight fast. BP was measured by the same person in the morning. After a 5&#x02010;min rest in a sitting position, BP was measured in triplicate to calculate the mean for assessment.</p></sec><sec id="jdi12004-sec-0009"><title>Analysis of Biomarkers</title><p>The primary objective of the present study was to evaluate the anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects of imidapril/losartan combination therapy by measuring the serum concentrations of high&#x02010;sensitivity CRP (hs&#x02010;CRP), sICAM&#x02010;1, IL&#x02010;18, MCP&#x02010;1 and aldosterone, as well as the urinary concentrations of IL&#x02010;18, MCP&#x02010;1, aldosterone and 8&#x02010;hydroxy&#x02010;2&#x02032;&#x02010;deoxyguanosine (8&#x02010;OHdG). Blood and urine samples were centrifuged immediately after collection, and the supernatants were stored at &#x02212;80 and &#x02212;30&#x000b0;C, respectively, until analysis. The concentrations of the pro&#x02010;inflammatory biomarkers were analyzed using samples obtained at baseline and at weeks&#x000a0;24 and 48. All samples were measured together once all specimens were collected.</p><p>An immunoturbidimetric assay was used for urinary albumin concentrations (Nitto Boseki Co. Ltd, Tokyo, Japan) and an immunonephelometric assay kit was used for hs&#x02010;CRP concentrations (Dade Behring, Marburg, Germany). Enzyme&#x02010;linked immunosorbent assay kits were used to measure IL&#x02010;18 (MBL, Nagoya, Japan), sICAM&#x02010;1 concentration and MCP&#x02010;1 concentrations (R&#x00026;D Systems, Inc, Minneapolis, MN, USA), and 8&#x02010;OHdG concentration (Nikken SEIL Co. Ltd, Tokyo, Japan). A radioimmunoassay kit was used to measure aldosterone concentrations (TFB Co. Ltd, Tokyo, Japan). A1C was measured using a high&#x02010;pressure liquid chromatography method and is expressed in National Glycohemoglobin Standardization Program values. The urinary markers were divided by the urinary creatinine concentration to calculate the creatinine ratio for assessment.</p></sec><sec id="jdi12004-sec-0010"><title>Statistical Analysis</title><p>Comparisons of baseline factors between the two therapeutic groups were analyzed by Student's unpaired <italic>t</italic>&#x02010;test for continuous parameters or chi&#x02010;squared&#x02010;test for categorical parameters (sex and previous therapy). Baseline concentrations of pro&#x02010;inflammatory markers, serum and urinary aldosterone concentrations, and urinary 8&#x02010;OHdG concentrations were compared using Student's unpaired <italic>t</italic>&#x02010;test. The percent change (% change) from baseline for pro&#x02010;inflammatory biomarkers, serum and urinary aldosterone concentrations, urinary 8&#x02010;OHdG concentration, A1C, BP,and C<sub>Cr</sub> at 24 and 48&#x000a0;weeks was calculated and analyzed by analysis of variance (<sc>anova</sc>). The differences in the percent change of these parameters at each time between the two therapeutic groups were analyzed by <sc>anova</sc>. All analyses were two&#x02010;sided with a significance level of 5%. Data are expressed as the number for categorical variables, mean change from baseline for percent changes and mean&#x000a0;&#x000b1;&#x000a0;standard deviation for continuous variables.</p></sec></sec><sec sec-type="results" id="jdi12004-sec-0011"><title>Results</title><p>A total of 36 patients who met the inclusion criteria were screened (Figure&#x000a0;<xref rid="jdi12004-fig-0001" ref-type="fig">1</xref>b). Before screening, all of the patients had received an ACEI and/or ARB. Four patients were excluded from the study during the washout period, including one patient who refused to participate in the study, two patients with an ACR&#x000a0;&#x0003c;&#x000a0;30&#x000a0;mg/gCr and one patient with C<sub>Cr</sub>&#x000a0;&#x0003c;&#x000a0;60&#x000a0;mL/min. Therefore, 32 patients started the study. In two patients allocated to combination therapy, the doses of losartan and imidapril were 25 and 2.5&#x000a0;mg/day, respectively, for the first 4&#x000a0;weeks because their systolic BP (SBP) was &#x0003c;120&#x000a0;mmHg. The doses in these patients were subsequently increased to 50 and 5&#x000a0;mg/day, respectively. During the observation period, two patients allocated to combination therapy were excluded from the study; one patient was hospitalized for hyperglycemia and one patient underwent surgery for colon carcinoma. In the monotherapy group, two patients were excluded during the observation period; one patient was hospitalized for pneumonia and one patient stopped visiting the hospital. Consequently, 14 patients in each therapeutic group, a total of 28 patients, completed 48&#x000a0;weeks of observation and were included in the analysis (Table&#x000a0;<xref rid="jdi12004-tbl-0001" ref-type="table-wrap">1</xref>). There were no significant differences in baseline parameters between the two therapeutic groups, including age, sex, duration of diabetes, body mass index, A1C, Ccr, SBP, diastolic BP (DBP), ACR and previous therapy.</p><table-wrap id="jdi12004-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline background of patients in each group</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Mono</th><th align="left" valign="top" rowspan="1" colspan="1">Combination</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">14</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">61.4&#x000a0;&#x000b1;&#x000a0;8.8</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">61.7&#x000a0;&#x000b1;&#x000a0;5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (male/female)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9/5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10/4</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of diabetes (years)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">11.7&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">15.6&#x000a0;&#x000b1;&#x000a0;6.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">25.4&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">24.5&#x000a0;&#x000b1;&#x000a0;5.1</td></tr><tr><td align="left" rowspan="1" colspan="1">A1C (%)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.8&#x000a0;&#x000b1;&#x000a0;1.5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">7.8&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">85.4&#x000a0;&#x000b1;&#x000a0;16.1</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">90.1&#x000a0;&#x000b1;&#x000a0;36.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">136&#x000a0;&#x000b1;&#x000a0;6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">134&#x000a0;&#x000b1;&#x000a0;12</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">79&#x000a0;&#x000b1;&#x000a0;6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">79&#x000a0;&#x000b1;&#x000a0;7</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin creatinine ratio (mg/gCr)</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">224&#x000a0;&#x000b1;&#x000a0;197</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">270&#x000a0;&#x000b1;&#x000a0;202</td></tr><tr><td align="left" colspan="3" rowspan="1">Medication (<italic>n</italic>)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Insulin</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Oral hyperglycemic agents</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1"> Statins</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">4</td></tr></tbody></table><table-wrap-foot><fn id="jdi12004-note-0001"><p>A1C, hemoglobin A1C; Mono, monotherapy.</p></fn><fn id="jdi12004-note-0002"><p>Data are <italic>n</italic> or mean&#x000a0;&#x000b1;&#x000a0;standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>None of the patients developed new cerebrovascular disease, cardiovascular disease, arteriosclerosis obliterans, progression of nephropathy, excessive BP decrease or hyperkalemia during the study. Urinalysis showed no evidence of ketonuria, hematuria or urinary tract infection.</p><sec id="jdi12004-sec-0012"><title>Time&#x02010;Course of A1C, BP and C<sub>Cr</sub></title><p>There were no significant differences in percent change in A1C at 8, 16, 24 or 48&#x000a0;weeks between the monotherapy (7.8&#x000a0;&#x000b1;&#x000a0;1.6, 8.0&#x000a0;&#x000b1;&#x000a0;1.2, 8.0&#x000a0;&#x000b1;&#x000a0;1.3 and 7.9&#x000a0;&#x000b1;&#x000a0;1.2%, respectively) and combination therapy groups (7.8&#x000a0;&#x000b1;&#x000a0;0.6, 8.1&#x000a0;&#x000b1;&#x000a0;1.0, 8.1&#x000a0;&#x000b1;&#x000a0;1.0 and 7.8&#x000a0;&#x000b1;&#x000a0;0.8%, respectively). Similarly, there were no significant differences in SBP (monotherapy 137&#x000a0;&#x000b1;&#x000a0;7, 136&#x000a0;&#x000b1;&#x000a0;8, 135&#x000a0;&#x000b1;&#x000a0;7 and 134&#x000a0;&#x000b1;&#x000a0;8&#x000a0;mmHg; combination therapy 134&#x000a0;&#x000b1;&#x000a0;12, 133&#x000a0;&#x000b1;&#x000a0;10, 137&#x000a0;&#x000b1;&#x000a0;10 and 134&#x000a0;&#x000b1;&#x000a0;9&#x000a0;mmHg), DBP (monotherapy 80&#x000a0;&#x000b1;&#x000a0;6, 79&#x000a0;&#x000b1;&#x000a0;7, 81&#x000a0;&#x000b1;&#x000a0;7 and 79&#x000a0;&#x000b1;&#x000a0;5&#x000a0;mmHg; combination therapy 79&#x000a0;&#x000b1;&#x000a0;8, 80&#x000a0;&#x000b1;&#x000a0;8, 80&#x000a0;&#x000b1;&#x000a0;8 and 78&#x000a0;&#x000b1;&#x000a0;8&#x000a0;mmHg) or C<sub>Cr</sub> (monotherapy 84.6&#x000a0;&#x000b1;&#x000a0;18.6, 85.2&#x000a0;&#x000b1;&#x000a0;20.4, 82.8&#x000a0;&#x000b1;&#x000a0;18.6 and 84.6&#x000a0;&#x000b1;&#x000a0;21.6&#x000a0;mL/min; combination therapy 85.2&#x000a0;&#x000b1;&#x000a0;31.8, 87.6&#x000a0;&#x000b1;&#x000a0;33.6, 86.4&#x000a0;&#x000b1;&#x000a0;34.2 and 86.4&#x000a0;&#x000b1;&#x000a0;30.6&#x000a0;mL/min) at 8, 16, 24 and 48&#x000a0;weeks of treatment.</p></sec><sec id="jdi12004-sec-0013"><title>Time&#x02010;Course of Serum Concentrations of Pro&#x02010;Inflammatory Biomarkers and Aldosterone</title><p>At baseline, we found no significant differences in the serum concentrations of hs&#x02010;CRP, sICAM&#x02010;1, IL&#x02010;18, MCP&#x02010;1 or aldosterone between the two groups (Table&#x000a0;<xref rid="jdi12004-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="jdi12004-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><title>Change of the serum levels of inflammatory molecules and aldosterone</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Serum molecules </th><th align="left" valign="top" rowspan="1" colspan="1">Week 0</th><th align="left" valign="top" rowspan="1" colspan="1">Week 24</th><th align="left" valign="top" rowspan="1" colspan="1">Week 48</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">hsCRP (mg/L)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.33&#x000a0;&#x000b1;&#x000a0;0.77</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.04&#x000a0;&#x000b1;&#x000a0;0.79</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">0.71&#x000a0;&#x000b1;&#x000a0;0.60 </td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;13.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;23.5<xref ref-type="fn" rid="jdi12004-note-0003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.39&#x000a0;&#x000b1;&#x000a0;0.93</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.24&#x000a0;&#x000b1;&#x000a0;1.01</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.04&#x000a0;&#x000b1;&#x000a0;0.75</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;0.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;16.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1.26&#x000a0;&#x000b1;&#x000a0;0.56</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">0.83&#x000a0;&#x000b1;&#x000a0;0.39</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">0.78&#x000a0;&#x000b1;&#x000a0;0.36</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;28.0<xref ref-type="fn" rid="jdi12004-note-0003">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;31.0<xref ref-type="fn" rid="jdi12004-note-0003">&#x02021;</xref></td></tr><tr><td align="left" colspan="4" rowspan="1">sICAM&#x02010;1 (pg/mL)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">275&#x000a0;&#x000b1;&#x000a0;76</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">256&#x000a0;&#x000b1;&#x000a0;74</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">250&#x000a0;&#x000b1;&#x000a0;54</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.9<xref ref-type="fn" rid="jdi12004-note-0003">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">282&#x000a0;&#x000b1;&#x000a0;96</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">265&#x000a0;&#x000b1;&#x000a0;100</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">262&#x000a0;&#x000b1;&#x000a0;65</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">269&#x000a0;&#x000b1;&#x000a0;52</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">247&#x000a0;&#x000b1;&#x000a0;35</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">238&#x000a0;&#x000b1;&#x000a0;38</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;10.6<xref ref-type="fn" rid="jdi12004-note-0003">&#x02021;</xref></td></tr><tr><td align="left" colspan="4" rowspan="1">IL&#x02010;18 (pg/mL)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">195&#x000a0;&#x000b1;&#x000a0;62</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">209&#x000a0;&#x000b1;&#x000a0;89</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">194&#x000a0;&#x000b1;&#x000a0;75</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+7.2</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">0.0 </td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">180&#x000a0;&#x000b1;&#x000a0;49</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">214&#x000a0;&#x000b1;&#x000a0;107</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">207&#x000a0;&#x000b1;&#x000a0;73</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+16.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+11.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">211&#x000a0;&#x000b1;&#x000a0;72</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">204&#x000a0;&#x000b1;&#x000a0;69</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">182&#x000a0;&#x000b1;&#x000a0;53</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;2.0 </td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.4<xref ref-type="fn" rid="jdi12004-note-0003">*</xref><xref ref-type="fn" rid="jdi12004-note-0003">&#x000a7;</xref></td></tr><tr><td align="left" colspan="4" rowspan="1">MCP&#x02010;1 (pg/mL)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">308&#x000a0;&#x000b1;&#x000a0;95</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">283&#x000a0;&#x000b1;&#x000a0;78</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">282&#x000a0;&#x000b1;&#x000a0;63</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.3<xref ref-type="fn" rid="jdi12004-note-0003">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.6<xref ref-type="fn" rid="jdi12004-note-0003">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">331&#x000a0;&#x000b1;&#x000a0;114</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">295&#x000a0;&#x000b1;&#x000a0;84</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">291&#x000a0;&#x000b1;&#x000a0;71</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.8 </td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;8.0 </td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">285&#x000a0;&#x000b1;&#x000a0;68</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">270&#x000a0;&#x000b1;&#x000a0;74</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">273&#x000a0;&#x000b1;&#x000a0;56</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;4.8</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;3.2</td></tr><tr><td align="left" colspan="4" rowspan="1">Aldosterone (pmol/L)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2470&#x000a0;&#x000b1;&#x000a0;1180</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2230&#x000a0;&#x000b1;&#x000a0;930</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1760&#x000a0;&#x000b1;&#x000a0;950</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;5.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;27.0<xref ref-type="fn" rid="jdi12004-note-0003">&#x02021;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2680&#x000a0;&#x000b1;&#x000a0;1220</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2510&#x000a0;&#x000b1;&#x000a0;840</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1860&#x000a0;&#x000b1;&#x000a0;1210</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+1.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;31.2<xref ref-type="fn" rid="jdi12004-note-0003">&#x02021;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">2260&#x000a0;&#x000b1;&#x000a0;1150</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1960&#x000a0;&#x000b1;&#x000a0;960</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">1650&#x000a0;&#x000b1;&#x000a0;610</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;12.1<xref ref-type="fn" rid="jdi12004-note-0003">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;22.7<xref ref-type="fn" rid="jdi12004-note-0003">&#x02020;</xref></td></tr></tbody></table><table-wrap-foot><fn id="jdi12004-note-0003"><p>Data are means&#x000a0;&#x000b1;&#x000a0;SD or frequencies (%).*<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05, &#x02020;<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.01, &#x02021;<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.005 versus baseline. <sup>&#x000a7;</sup><italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05 for combination versus monotherapy (Mono).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>In all patients, the serum hs&#x02010;CRP concentration decreased significantly from baseline by 23.5% at 48&#x000a0;weeks. In the combination therapy group, the serum hs&#x02010;CRP concentration decreased significantly from baseline by 28.0 and 31.0% at 24 and 48&#x000a0;weeks, respectively. The serum hs&#x02010;CRP concentration decreased by 16.6% at 48&#x000a0;weeks in the monotherapy group, although not significantly (Table&#x000a0;<xref rid="jdi12004-tbl-0002" ref-type="table-wrap">2</xref>). The serum sICAM&#x02010;1 concentration decreased significantly by 10.6% at 48&#x000a0;weeks in the combination therapy group, but did not change significantly in the monotherapy group (Table&#x000a0;<xref rid="jdi12004-tbl-0002" ref-type="table-wrap">2</xref>). The serum IL&#x02010;18 concentration decreased significantly by 11.4% at 48&#x000a0;weeks in the combination therapy group, but tended to increase in the monotherapy group, resulting in a significant difference in the percent change between the two groups at 48&#x000a0;weeks (Table&#x000a0;<xref rid="jdi12004-tbl-0002" ref-type="table-wrap">2</xref>). In all patients, the serum MCP&#x02010;1 concentration decreased significantly from baseline by 6.3 and 5.6% at 24 and 48&#x000a0;weeks, respectively. The serum MCP&#x02010;1 concentration decreased in both therapeutic groups, although the percent change was not significant. The serum aldosterone concentration decreased significantly from baseline at 48&#x000a0;weeks in all patients and in both groups (Table&#x000a0;<xref rid="jdi12004-tbl-0002" ref-type="table-wrap">2</xref>).</p></sec><sec id="jdi12004-sec-0014"><title>Time&#x02010;Course of ACR and Urinary Concentrations of IL&#x02010;18, MCP&#x02010;1, Aldosterone and 8&#x02010;OHdG</title><p>At baseline, there were no significant differences between the two groups in ACR or urinary concentrations of IL&#x02010;18, MCP&#x02010;1, aldosterone or 8&#x02010;OHdG (Table&#x000a0;<xref rid="jdi12004-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="jdi12004-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><title>Change of the urinary levels of albumin/creatinine ratio, inflammatory molecules, aldosterone and 8&#x02010;hydroxy&#x02010;2&#x02032;&#x02010;deoxyguanosine</title></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" width="1" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Urinary molecules </th><th align="left" valign="top" rowspan="1" colspan="1">Week 0</th><th align="left" valign="top" rowspan="1" colspan="1">Week 24</th><th align="left" valign="top" rowspan="1" colspan="1">Week 48</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">ACR (mg/gCr)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">252&#x000a0;&#x000b1;&#x000a0;197</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">200&#x000a0;&#x000b1;&#x000a0;202</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">175&#x000a0;&#x000b1;&#x000a0;159</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;8.3<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;11.0<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">234&#x000a0;&#x000b1;&#x000a0;197</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">209&#x000a0;&#x000b1;&#x000a0;221</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">182&#x000a0;&#x000b1;&#x000a0;128</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;3.5</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;6.2<xref ref-type="fn" rid="jdi12004-note-0004">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">270&#x000a0;&#x000b1;&#x000a0;202</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">192&#x000a0;&#x000b1;&#x000a0;189</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">168&#x000a0;&#x000b1;&#x000a0;191</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;12.8<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref><xref ref-type="fn" rid="jdi12004-note-0004">&#x000a7;</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.4<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref><xref ref-type="fn" rid="jdi12004-note-0004">&#x000a7;</xref></td></tr><tr><td align="left" colspan="4" rowspan="1">IL&#x02010;18 (pg/mL/Cr)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">57&#x000a0;&#x000b1;&#x000a0;62</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">33&#x000a0;&#x000b1;&#x000a0;34</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">13&#x000a0;&#x000b1;&#x000a0;14</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.7</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;24.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">39&#x000a0;&#x000b1;&#x000a0;35</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">25&#x000a0;&#x000b1;&#x000a0;17</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">19&#x000a0;&#x000b1;&#x000a0;17</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;7.3</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+6.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">75&#x000a0;&#x000b1;&#x000a0;77</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">40&#x000a0;&#x000b1;&#x000a0;45</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8&#x000a0;&#x000b1;&#x000a0;8</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;24.1 </td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;55.3<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref><xref ref-type="fn" rid="jdi12004-note-0004">&#x000a7;</xref></td></tr><tr><td align="left" colspan="4" rowspan="1">MCP&#x02010;1 (pg/mL/Cr)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">318&#x000a0;&#x000b1;&#x000a0;192</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">205&#x000a0;&#x000b1;&#x000a0;101</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">340&#x000a0;&#x000b1;&#x000a0;244</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+22.4<xref ref-type="fn" rid="jdi12004-note-0004">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">341&#x000a0;&#x000b1;&#x000a0;220</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">216&#x000a0;&#x000b1;&#x000a0;109</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">351&#x000a0;&#x000b1;&#x000a0;216</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+32.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">294&#x000a0;&#x000b1;&#x000a0;164</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">195&#x000a0;&#x000b1;&#x000a0;95</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">329&#x000a0;&#x000b1;&#x000a0;277</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.4</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">+12.0</td></tr><tr><td align="left" colspan="4" rowspan="1">Aldosterone (pmol/L/Cr)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">100&#x000a0;&#x000b1;&#x000a0;70</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">48&#x000a0;&#x000b1;&#x000a0;45</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">68&#x000a0;&#x000b1;&#x000a0;54</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;50.9<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;29.1<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">125&#x000a0;&#x000b1;&#x000a0;79</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">68&#x000a0;&#x000b1;&#x000a0;52</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">89&#x000a0;&#x000b1;&#x000a0;59</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;35.7<xref ref-type="fn" rid="jdi12004-note-0004">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;22.6<xref ref-type="fn" rid="jdi12004-note-0004">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">77&#x000a0;&#x000b1;&#x000a0;68</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">29&#x000a0;&#x000b1;&#x000a0;28</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">47&#x000a0;&#x000b1;&#x000a0;41</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;65.1<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;35.2</td></tr><tr><td align="left" colspan="4" rowspan="1">8&#x02010;OHdG (pg/mL/Cr)</td></tr><tr><td align="left" rowspan="1" colspan="1">All patients</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.8&#x000a0;&#x000b1;&#x000a0;5.0 </td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8.2&#x000a0;&#x000b1;&#x000a0;4.2</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">8.6&#x000a0;&#x000b1;&#x000a0;3.4</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;28.6<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;26.6<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Mono</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">13.7&#x000a0;&#x000b1;&#x000a0;3.8</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">9.7&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">10.7&#x000a0;&#x000b1;&#x000a0;3.1</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;23.8<xref ref-type="fn" rid="jdi12004-note-0004">*</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;15.4<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Combination</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">12.0 &#x000a0;&#x000b1;&#x000a0;5.9</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.8&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">6.5&#x000a0;&#x000b1;&#x000a0;2.3</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">% change</td><td align="left" rowspan="1" colspan="1"/><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;33.5<xref ref-type="fn" rid="jdi12004-note-0004">&#x02020;</xref></td><td align="left" char="&#x000b1;" rowspan="1" colspan="1">&#x02212;37.8<xref ref-type="fn" rid="jdi12004-note-0004">&#x02021;</xref><xref ref-type="fn" rid="jdi12004-note-0004">&#x000a7;</xref></td></tr></tbody></table><table-wrap-foot><fn id="jdi12004-note-0004"><p>Data are means&#x000a0;&#x000b1;&#x000a0;SD or frequencies (%). *<italic>P&#x000a0;</italic>&#x0003c;&#x000a0;0.05, &#x02020;<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.01, &#x02021;<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.005 versus baseline. &#x000a7;<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05 for combination versus monotherapy (Mono).</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>In all patients, ACR decreased significantly by 8.3 and 11.0% at 24 and 48&#x000a0;weeks, respectively. ACR decreased significantly by 6.2% at 48&#x000a0;weeks in the monotherapy group and by 12.8 and 15.4% at 24 and 48&#x000a0;weeks, respectively, in the combination therapy group. The percent change (decrease) in ACR was significantly greater in the combination therapy group than in the monotherapy group at both times (Table&#x000a0;<xref rid="jdi12004-tbl-0003" ref-type="table-wrap">3</xref>). In all patients, the urinary IL&#x02010;18 concentration tended to decrease over time, although not significantly. In the combination therapy group, the urinary IL&#x02010;18 concentration decreased significantly by 55.3% at 48&#x000a0;weeks, and the percent change was significantly different from that in the monotherapy group (Table&#x000a0;<xref rid="jdi12004-tbl-0003" ref-type="table-wrap">3</xref>). In all patients, the urinary MCP&#x02010;1 concentration decreased by 15.4% at 24&#x000a0;weeks, but increased significantly by 22.4% at 48&#x000a0;weeks. In both groups, the urinary MCP&#x02010;1 concentration was increased at 48&#x000a0;weeks. The urinary aldosterone concentration was significantly decreased at all times in all patients and in both treatment groups; however, there were no significant differences in the percent changes between the two groups (Table&#x000a0;<xref rid="jdi12004-tbl-0003" ref-type="table-wrap">3</xref>). In all patients, the urinary 8&#x02010;OHdG concentration decreased significantly from baseline by 28.6 and 26.6% at 24 and 48&#x000a0;weeks, respectively. The urinary 8&#x02010;OHdG concentration decreased significantly by 23.8% at 24&#x000a0;weeks in the monotherapy group and by 33.5 and 37.8% at 24 and 48&#x000a0;weeks, respectively, in the combination therapy group. The percent change in 8&#x02010;OHdG concentration at 48&#x000a0;weeks was significantly greater in the combination therapy group than in the monotherapy group (Table&#x000a0;<xref rid="jdi12004-tbl-0003" ref-type="table-wrap">3</xref>).</p></sec></sec><sec sec-type="discussion" id="jdi12004-sec-0015"><title>Discussion</title><p>The present study showed that treatment with losartan and imidapril was more effective than treatment with amlodipine in decreasing ACR as well as inflammatory and oxidative stress markers in serum and urine in Japanese patients with type&#x000a0;2 diabetes and nephropathy. These effects were maintained for 48&#x000a0;week. Combination therapy with losartan and imidapril was more useful in decreasing ACR, and pro&#x02010;inflammatory and oxidative stress markers than losartan administered at a double dose, without differences in BP or glycemic control. These results suggest that the losartan/imidapril combination might be useful to prevent the progression of atherosclerosis and nephropathy in patients with type&#x000a0;2 diabetes by exerting anti&#x02010;inflammatory and anti&#x02010;oxidative effects through inhibition of the RAS.</p><p>The RAS and downstream inflammatory activities are involved in the progression of atherosclerosis<xref rid="jdi12004-bib-0016" ref-type="ref">16</xref>. In the present study, treatment with losartan and imidapril did not significantly change A1C or BP, but hs&#x02010;CRP levels at 24 and 48&#x000a0;weeks, and sICAM&#x02010;1 levels at 48&#x000a0;weeks were significantly lower than those at baseline; these changes were not observed in the monotherapy group. Amlodipine was reported to have anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects, and to inhibit the production of hs&#x02010;CRP and sICAM&#x02010;1<xref rid="jdi12004-bib-0017 jdi12004-bib-0018" ref-type="ref">17</xref>. RAS inhibitors also have anti&#x02010;inflammatory effects, which are favorable cardiovascular effects, independent of their antihypertensive effects<xref rid="jdi12004-bib-0019 jdi12004-bib-0020" ref-type="ref">19</xref>. The present study showed that losartan and imidapril could inhibit the progression of atherosclerosis by their anti&#x02010;inflammatory effects through inhibition of the RAS more potently than amlodipine.</p><p>The serum IL&#x02010;18 concentration tended to be increased in the monotherapy group, but decreased significantly in the combination therapy group, resulting in a significant difference between the two groups at 48&#x000a0;weeks. Serum IL&#x02010;18 is an important prognostic predictor of diabetic nephropathy and atherosclerosis<xref rid="jdi12004-bib-0021" ref-type="ref">21</xref>. It has been reported that ARBs and ACEIs decrease IL&#x02010;18 by inhibiting the RAS<xref rid="jdi12004-bib-0022" ref-type="ref">22</xref>. In the present study, amlodipine was only administered during the washout period. Therefore, the efficacy of losartan and imidapril represented the change from treatment with amlodipine. Based on our searches of the literature, amlodipine has no known effect on serum IL&#x02010;18 concentrations. These results indicate that imidapril/losartan combination therapy could have better anti&#x02010;inflammatory efficacy in patients with type&#x000a0;2 diabetes with nephropathy, as compared with amlodipine or losartan monotherapy.</p><p>Similar to microinflammation, oxidative stress is profoundly involved in the development of atherosclerosis and diabetic complications<xref rid="jdi12004-bib-0023" ref-type="ref">23</xref>. 8&#x02010;OHdG is a biomarker of systemic DNA damage in diabetic nephropathy<xref rid="jdi12004-bib-0024" ref-type="ref">24</xref>. In the present study, the urinary 8&#x02010;OHdG concentration decreased significantly after treatment with losartan and imidapril, as compared with baseline levels. The decrease in urinary 8&#x02010;OHdG concentrations was greater in the combination therapy group than in the monotherapy group. It has been reported that amlodipine<xref rid="jdi12004-bib-0017 jdi12004-bib-0018" ref-type="ref">17</xref>, ACEI<xref rid="jdi12004-bib-0011" ref-type="ref">11</xref> and ARB<xref rid="jdi12004-bib-0012 jdi12004-bib-0019" ref-type="ref">12</xref> suppress oxidative stress. However, it is unclear which of these agents or which combination of these drugs elicits the greatest reduction in oxidative stress in patients with diabetic nephropathy. The present results suggest that imidapril/losartan combination therapy might be more effective in preventing the development or progression of diabetic nephropathy because of its more potent inhibitory effects on oxidative stress than losartan monotherapy. These effects were maintained for up to 48&#x000a0;weeks.</p><p>The urinary aldosterone concentration was also decreased more markedly by combination therapy than monotherapy in the present study, which suggests that combination therapy more potently inhibits the RAS in the kidney. The urinary IL&#x02010;18 concentration was also significantly decreased by combination therapy as compared with monotherapy. We previously reported that serum and urine IL&#x02010;18 concentrations are predictors of diabetic nephropathy<xref rid="jdi12004-bib-0021" ref-type="ref">21</xref>. IL&#x02010;18 secretion in monocytes and macrophages is stimulated by inflammation and oxidative stress associated with hyperglycemia<xref rid="jdi12004-bib-0025" ref-type="ref">25</xref>. These results suggest that the combination of losartan and imidapril might be useful to prevent the development of early nephropathy in patients with type&#x000a0;2 diabetes by decreasing ACR, and reducing inflammation and oxidative stress in the kidney through more potent inhibition of the RAS.</p><p>The main limitation of the present study was that the observation period was not long enough to evaluate renal or cardiovascular outcomes. The Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)<xref rid="jdi12004-bib-0026" ref-type="ref">26</xref>, and Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial (ONTARGET)<xref rid="jdi12004-bib-0027" ref-type="ref">27</xref> studies both showed that combination therapy with an ACEI and an ARB did not have significant benefits on renal outcomes. However, in the ORIENT study<xref rid="jdi12004-bib-0026" ref-type="ref">26</xref>, combination therapy with olmesartan and an ACEI reduced proteinuria, as observed in the present study, but did not further improve renal or cardiovascular outcomes. The reason for these discrepancies remains unclear. Further studies are required to confirm the beneficial effect of combination therapy with an ARB and an ACEI on renal and cardiovascular outcomes in patients with type&#x000a0;2 diabetes and nephropathy.</p><p>In the present study, the sample size of 28 patients was small, meaning larger studies are required to confirm these results. Although the serum and urinary concentrations of several biomarkers decreased after monotherapy or combination therapy, some changes were not statistically significant, perhaps because of the small sample size. Although amlodipine was used during the washout period to prevent possible changes in BP, we measured ambulatory BP at a single time, so we cannot exclude the possible effects of BP on the decrease in ACR. A larger clinical study using 24&#x02010;h BP monitoring might be required to verify the results of the present study.</p><p>In conclusion, a combination of an ACEI and an ARB could be beneficial for treating diabetic nephropathy through their anti&#x02010;inflammatory and anti&#x02010;oxidative stress effects.</p></sec></body><back><ack id="jdi12004-sec-0016"><title>Acknowledgements</title><p>This study was supported in part by a Grant&#x02010;in&#x02010;Aid for Scientific Research (C) to K Shikata (21591031), a Grant&#x02010;in&#x02010;Aid for Young Scientists (B) to D Ogawa (23790942) from the Ministry of Education, Culture, Sports, Science and Technology, and by a Grant&#x02010;in&#x02010;Aid for Diabetic Nephropathy Research from the Ministry of Health, Labour and Welfare of Japan. This work was also supported by the Takeda Science Foundation, the Naito Foundation, the Japan Foundation for Applied Enzymology, and the Ryobi Teien Memory Foundation. We thank the staff at Okayama Saiseikai General Hospital for their cooperation in this study. The authors have no potential conflicts of interest relevant to this study to report.</p></ack><ref-list content-type="cited-references" id="jdi12004-bibl-0001"><title>References</title><ref id="jdi12004-bib-0001"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Ross</surname>
<given-names>R</given-names></string-name>. <article-title>Atherosclerosis&#x02010;an inflammatory disease</article-title>. <source>N Engl J Med</source><year>1990</year>; <volume>340</volume>: <fpage>115</fpage>&#x02013;<lpage>126</lpage><pub-id pub-id-type="pmid">9887164</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0002"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Fornoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ijaz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tejada</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Role of inflammation in diabetic nephropathy</article-title>. <source>Curr Diabetes Rev</source><year>2008</year>; <volume>4</volume>: <fpage>10</fpage>&#x02013;<lpage>17</lpage><pub-id pub-id-type="pmid">18220690</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0003"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>Navarro&#x02010;Gonz&#x000e1;lez</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Mora&#x02010;Fern&#x000e1;ndez</surname>
<given-names>C</given-names></string-name>. <article-title>The role of inflammatory cytokines in diabetic nephropathy</article-title>. <source>J Am Soc Nephrol</source><year>2008</year>; <volume>19</volume>: <fpage>433</fpage>&#x02013;<lpage>442</lpage><pub-id pub-id-type="pmid">18256353</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0004"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Blake</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Rifai</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Buring</surname>
<given-names>JE</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Blood pressure, C&#x02010;reactive protein, and risk of future cardiovascular events</article-title>. <source>Circulation</source><year>2003</year>; <volume>108</volume>: <fpage>2993</fpage>&#x02013;<lpage>2999</lpage><pub-id pub-id-type="pmid">14638538</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0005"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Abrahamian</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Endler</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Exner</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Association of low&#x02010;grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP&#x02010;levels and 2 different gene&#x02010;polymorphisms of proinflammatory cytokines</article-title>. <source>Exp Clin Endocrinol Diabetes</source><year>2007</year>; <volume>115</volume>: <fpage>38</fpage>&#x02013;<lpage>41</lpage><pub-id pub-id-type="pmid">17286233</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0006"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ritz</surname>
<given-names>E</given-names></string-name>. <article-title>Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications</article-title>. <source>Kidney Int</source><year>2005</year>; <volume>67</volume>: <fpage>799</fpage>&#x02013;<lpage>812</lpage><pub-id pub-id-type="pmid">15698420</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0007"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Ferrari</surname>
<given-names>P</given-names></string-name>. <article-title>Prescribing angiotensin&#x02010;converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease</article-title>. <source>Nephrology</source><year>2007</year>; <volume>12</volume>: <fpage>81</fpage>&#x02013;<lpage>89</lpage><pub-id pub-id-type="pmid">17295666</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0008"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Tomohiro</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kumai</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sato</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy</article-title>. <source>Life Sci</source><year>2007</year>; <volume>80</volume>: <fpage>1364</fpage>&#x02013;<lpage>1372</lpage><pub-id pub-id-type="pmid">17331548</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0009"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Descamps&#x02010;Latscha</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Witko&#x02010;Sarsat</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Nguyen&#x02010;Khoa</surname>
<given-names>T</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients</article-title>. <source>Am J Kidney Dis</source><year>2005</year>; <volume>45</volume>: <fpage>39</fpage>&#x02013;<lpage>47</lpage><pub-id pub-id-type="pmid">15696442</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0010"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Mori</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Cowley</surname>
<given-names>AW</given-names>
<suffix>Jr</suffix></string-name>. <article-title>Role of pressure in angiotensin II&#x02010;induced renal injury: chronic servo&#x02010;control of renal perfusion pressure in rats</article-title>. <source>Hypertension</source><year>2004</year>; <volume>43</volume>: <fpage>752</fpage>&#x02013;<lpage>759</lpage><pub-id pub-id-type="pmid">14981064</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0011"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Tojo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Onozato</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Kobayashi</surname>
<given-names>N</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Angiotensin II and oxidative stress in Dahl Salt&#x02010;sensitive rat with heart failure</article-title>. <source>Hypertension</source><year>2002</year>; <volume>40</volume>: <fpage>834</fpage>&#x02013;<lpage>839</lpage><pub-id pub-id-type="pmid">12468566</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0012"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Ogawa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mori</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nako</surname>
<given-names>K</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy</article-title>. <source>Hypertension</source><year>2006</year>; <volume>47</volume>: <fpage>699</fpage>&#x02013;<lpage>705</lpage><pub-id pub-id-type="pmid">16505207</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0013"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Kunz</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Friedrich</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wolbers</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Meta&#x02010;analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease</article-title>. <source>Ann Intern Med</source><year>2008</year>; <volume>148</volume>: <fpage>30</fpage>&#x02013;<lpage>48</lpage><pub-id pub-id-type="pmid">17984482</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0014"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Jennings</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Kalus</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>CI</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta&#x02010;analysis</article-title>. <source>Diabet Med</source><year>2007</year>; <volume>24</volume>: <fpage>486</fpage>&#x02013;<lpage>493</lpage><pub-id pub-id-type="pmid">17367311</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0015"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Yusuf</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Teo</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Pogue</surname>
<given-names>J</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events</article-title>. <source>N Engl J Med</source><year>2008</year>; <volume>358</volume>: <fpage>1547</fpage>&#x02013;<lpage>1559</lpage><pub-id pub-id-type="pmid">18378520</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0016"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Ferrario</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Strawn</surname>
<given-names>WB</given-names></string-name>. <article-title>Role of the renin&#x02010;angiotensin&#x02010;aldosterone system and proinflammatory mediators in cardiovascular disease</article-title>. <source>Am J Cardiol</source><year>2006</year>; <volume>98</volume>: <fpage>121</fpage>&#x02013;<lpage>128</lpage><pub-id pub-id-type="pmid">16784934</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0017"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Yoshii</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Iwai</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Regression of atherosclerosis by amlodipine via anti&#x02010;inflammatory and anti&#x02010;oxidative stress actions</article-title>. <source>Hypertens Res</source><year>2006</year>; <volume>29</volume>: <fpage>457</fpage>&#x02013;<lpage>466</lpage><pub-id pub-id-type="pmid">16940709</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0018"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Kataoka</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Egashira</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ishibashi</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Novel anti&#x02010;inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long&#x02010;term inhibition of nitric oxide synthesis</article-title>. <source>Am J Physiol Heart Circ Physiol</source><year>2004</year>; <volume>286</volume>: <fpage>768</fpage>&#x02013;<lpage>774</lpage></mixed-citation></ref><ref id="jdi12004-bib-0019"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Koh</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Ahn</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>SH</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients</article-title>. <source>J Am Coll Cardiol</source><year>2003</year>; <volume>42</volume>: <fpage>905</fpage>&#x02013;<lpage>910</lpage><pub-id pub-id-type="pmid">12957441</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0020"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Iwai</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>L</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Important role of nitric oxide in the effect of angiotensin&#x02010;converting enzyme inhibitor imidapril on vascular injury</article-title>. <source>Hypertension</source><year>2003</year>; <volume>42</volume>: <fpage>542</fpage>&#x02013;<lpage>547</lpage><pub-id pub-id-type="pmid">12963679</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0021"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Nakamura</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shikata</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hiramatsu</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Serum interleukin&#x02010;18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes</article-title>. <source>Diabetes Care</source><year>2005</year>; <volume>28</volume>: <fpage>2890</fpage>&#x02013;<lpage>2895</lpage><pub-id pub-id-type="pmid">16306550</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0022"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Lapteva</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ide</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nieda</surname>
<given-names>M</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Activation and suppression of renin&#x02010;angiotensin system in human dendritic cells</article-title>. <source>Biochem Biophys Res Commun</source><year>2002</year>; <volume>296</volume>: <fpage>194</fpage>&#x02013;<lpage>200</lpage><pub-id pub-id-type="pmid">12147250</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0023"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Pan</surname>
<given-names>HZ</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>LG</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Oxidative damage to DNA and its relationship with diabetic complications</article-title>. <source>Biomed Environ Sci</source><year>2007</year>; <volume>20</volume>: <fpage>160</fpage>&#x02013;<lpage>163</lpage><pub-id pub-id-type="pmid">17624192</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0024"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Xu</surname>
<given-names>GW</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>QH</given-names></string-name>, <string-name><surname>Weng</surname>
<given-names>QF</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Study of urinary 8&#x02010;hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients</article-title>. <source>J Pharm Biomed Anal</source><year>2004</year>; <volume>36</volume>: <fpage>101</fpage>&#x02013;<lpage>104</lpage><pub-id pub-id-type="pmid">15351053</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0025"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Arnalich</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Hernanz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lopez&#x02010;Maderuelo</surname>
<given-names>D</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Enhanced acute&#x02010;phase response and oxidative stress in older adults with type II diabetes</article-title>. <source>Horm Metab Res</source><year>2000</year>; <volume>32</volume>: <fpage>407</fpage>&#x02013;<lpage>412</lpage><pub-id pub-id-type="pmid">11069205</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0026"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Imai</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Ito</surname>
<given-names>S</given-names></string-name>, <italic>et&#x000a0;al</italic>
<article-title>Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo&#x02010;controlled study</article-title>. <source>Diabetologia</source><year>2011</year>; <volume>54</volume>: <fpage>2978</fpage>&#x02013;<lpage>2986</lpage><pub-id pub-id-type="pmid">21993710</pub-id></mixed-citation></ref><ref id="jdi12004-bib-0027"><label>27</label><mixed-citation publication-type="journal"><collab collab-type="authors">ONTARGET Investigators</collab>
. <article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events</article-title>. <source>N Engl J Med</source><year>2008</year>; <volume>358</volume>: <fpage>1547</fpage>&#x02013;<lpage>1559</lpage><pub-id pub-id-type="pmid">18378520</pub-id></mixed-citation></ref></ref-list></back></article>